Goldman Sachs’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,144,560
| Closed | -$45.5M | – | 6621 |
|
|
2026
Q1 | $45.5M | Buy |
1,144,560
+365,559
| +47% | +$9.35M | 0.01% | 1654 |
|
|
2025
Q4 | $19.5M | Buy |
779,001
+531,446
| +215% | +$13.5M | ﹤0.01% | 2399 |
|
|
2025
Q3 | $6M | Sell |
247,555
-311,728
| -56% | -$5.54M | ﹤0.01% | 3487 |
|
|
2025
Q2 | $7.35M | Buy |
559,283
+157,519
| +39% | +$2M | ﹤0.01% | 3053 |
|
|
2025
Q1 | $5.78M | Buy |
401,764
+226,198
| +129% | +$3.7M | ﹤0.01% | 3209 |
|
|
2024
Q4 | $2.94M | Buy |
175,566
+162,511
| +1,245% | +$2.69M | ﹤0.01% | 3968 |
|
|
2024
Q3 | $209K | Buy |
+13,055
| New | +$160K | ﹤0.01% | 5441 |
|
|
2024
Q2 | – | Sell |
-55,027
| Closed | -$622K | – | 5683 |
|
|
2024
Q1 | $622K | Buy |
55,027
+30,296
| +123% | +$287K | ﹤0.01% | 4634 |
|
|
2023
Q4 | $197K | Buy |
24,731
+14,081
| +132% | +$94.4K | ﹤0.01% | 5160 |
|
|
2023
Q3 | $68.9K | Hold |
10,650
| – | – | ﹤0.01% | 5240 |
|
|
2023
Q2 | $65.9K | Sell |
10,650
-310
| -3% | -$1.47K | ﹤0.01% | 5425 |
|
|
2023
Q1 | $42.2K | Sell |
10,960
-4,033
| -27% | -$14.8K | ﹤0.01% | 5575 |
|
|
2022
Q4 | $46.5K | Sell |
14,993
-1,536
| -9% | -$5.69K | ﹤0.01% | 5607 |
|
|
2022
Q3 | $66K | Sell |
16,529
-14
| -0.1% | -$64 | ﹤0.01% | 5766 |
|
|
2022
Q2 | $81K | Buy |
+16,543
| New | +$106K | ﹤0.01% | 5921 |
|
Goldman Sachs's CNTA Position: Q2 2026 in Review
Goldman Sachs sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 1,144,560 shares — an estimated $45.5M sold.
Goldman Sachs first reported a position in CNTA in Q2 2022 and held it in 15 quarters. The position peaked at $45.5M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.
- Goldman Sachs reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Goldman Sachs sold 1,144,560 Centessa Pharmaceuticals shares in Q2 2026, an estimated $45.5M.
- Goldman Sachs first reported a position in Centessa Pharmaceuticals in Q2 2022 and held it in 15 quarters.
- Goldman Sachs's Centessa Pharmaceuticals position peaked at $45.5M in Q1 2026.
- 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.